Lokesh Jain

3.1k total citations
57 papers, 2.3k citations indexed

About

Lokesh Jain is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Lokesh Jain has authored 57 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 10 papers in Molecular Biology. Recurrent topics in Lokesh Jain's work include Cancer Immunotherapy and Biomarkers (12 papers), CAR-T cell therapy research (7 papers) and Colorectal Cancer Treatments and Studies (6 papers). Lokesh Jain is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), CAR-T cell therapy research (7 papers) and Colorectal Cancer Treatments and Studies (6 papers). Lokesh Jain collaborates with scholars based in United States, India and United Kingdom. Lokesh Jain's co-authors include William D. Figg, Jürgen Venitz, William L. Dahut, Elise C. Kohn, Seth M. Steinberg, Vikram Sinha, Erin R. Gardner, James R. Wright, William D. Figg and Kapil Mayawala and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Lokesh Jain

53 papers receiving 2.2k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Lokesh Jain 931 741 578 345 258 57 2.3k
Gennaro Daniele 970 1.0× 559 0.8× 577 1.0× 262 0.8× 159 0.6× 100 1.9k
Pascaline Boudou‐Rouquette 1.4k 1.5× 644 0.9× 1.2k 2.0× 323 0.9× 176 0.7× 133 2.9k
Andrew Lake 1.5k 1.6× 768 1.0× 782 1.4× 736 2.1× 218 0.8× 15 3.3k
Muhammad Wasif Saif 1.7k 1.8× 562 0.8× 639 1.1× 222 0.6× 180 0.7× 129 2.7k
Julie Hambleton 1.1k 1.2× 556 0.8× 598 1.0× 221 0.6× 318 1.2× 31 3.0k
Laleh G. Melstrom 1.2k 1.3× 608 0.8× 694 1.2× 461 1.3× 258 1.0× 147 2.9k
Ana Ruiz-Garcı́a 952 1.0× 622 0.8× 806 1.4× 159 0.5× 201 0.8× 65 2.0k
Michael B. Jameson 780 0.8× 737 1.0× 309 0.5× 450 1.3× 84 0.3× 104 2.0k
Gianpiero Fasola 2.0k 2.2× 598 0.8× 1.3k 2.2× 625 1.8× 257 1.0× 175 3.2k

Countries citing papers authored by Lokesh Jain

Since Specialization
Citations

This map shows the geographic impact of Lokesh Jain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lokesh Jain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lokesh Jain more than expected).

Fields of papers citing papers by Lokesh Jain

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lokesh Jain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lokesh Jain. The network helps show where Lokesh Jain may publish in the future.

Co-authorship network of co-authors of Lokesh Jain

This figure shows the co-authorship network connecting the top 25 collaborators of Lokesh Jain. A scholar is included among the top collaborators of Lokesh Jain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lokesh Jain. Lokesh Jain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tourneau, C. Le, C. Even, Assuntina G. Sacco, et al.. (2024). 411MO Petosemtamab (MCLA-158) monotherapy in previously treated (2L+) recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase II trial. Annals of Oncology. 35. S1557–S1558. 2 indexed citations
2.
Jain, Mukesh, et al.. (2023). Hepatoprotective Effects of Liv.52 in Chronic Liver Disease Preclinical, Clinical, and Safety Evidence: A Review. Gastroenterology Insights. 14(3). 293–308. 6 indexed citations
3.
Marathe, Dhananjay, Huub Jan Kleijn, Anne Chain, et al.. (2023). Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling. CPT Pharmacometrics & Systems Pharmacology. 12(10). 1499–1510. 11 indexed citations
4.
5.
Schalkwijk, Stein, Li Zhou, Lokesh Jain, et al.. (2021). Population pharmacokinetics and exposure–response of selumetinib and its N‐desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas. Cancer Chemotherapy and Pharmacology. 88(2). 189–202. 10 indexed citations
6.
Atkins, Michael B., F. Stephen Hodi, John A. Thompson, et al.. (2018). Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. Clinical Cancer Research. 24(8). 1805–1815. 48 indexed citations
7.
Turner, David C., Anna Kondic, Keaven M. Anderson, et al.. (2018). Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance. Clinical Cancer Research. 24(23). 5841–5849. 156 indexed citations
8.
Gantz, Ira, Л.К. Соколова, Lokesh Jain, et al.. (2017). Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds. Clinical Therapeutics. 39(10). 2024–2037. 5 indexed citations
9.
Nolin, Thomas D., George R. Aronoff, William H. Fissell, et al.. (2014). Pharmacokinetic Assessment in Patients Receiving Continuous RRT. Clinical Journal of the American Society of Nephrology. 10(1). 159–164. 35 indexed citations
10.
Peer, Cody J., Tristan M. Sissung, AeRang Kim, et al.. (2012). Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia. Clinical Cancer Research. 18(7). 2099–2107. 108 indexed citations
11.
Jain, Lokesh, Barjesh Chander Sharma, Praveen Sharma, et al.. (2012). Serum endotoxin and inflammatory mediators in patients with cirrhosis and hepatic encephalopathy. Digestive and Liver Disease. 44(12). 1027–1031. 47 indexed citations
12.
Rajan, Arun, Ronan J. Kelly, Jane B. Trepel, et al.. (2011). A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas. Clinical Cancer Research. 17(21). 6831–6839. 107 indexed citations
13.
Jain, Lokesh, Sukyung Woo, Erin R. Gardner, et al.. (2011). Population pharmacokinetic analysis of sorafenib in patients with solid tumours. British Journal of Clinical Pharmacology. 72(2). 294–305. 114 indexed citations
14.
Jain, Rajul K., Sang M. Chung, Lokesh Jain, et al.. (2011). Implications of Obesity for Drug Therapy: Limitations and Challenges. Clinical Pharmacology & Therapeutics. 90(1). 77–89. 157 indexed citations
15.
Bhattacharjee, Harsha, et al.. (2010). Clinical presentation and outcomes following posterior segment IOFB. SHILAP Revista de lepidopterología. 21(3). 42–47. 2 indexed citations
16.
Jain, Lokesh, Sophia Abraham, & Stacy S. Shord. (2010). The Interactions of Anti-Cancer Drugs Approved in the Last Decade in the United States with Membrane Transporters. Anti-Cancer Agents in Medicinal Chemistry. 10(8). 601–616. 3 indexed citations
17.
Jain, Lokesh, Craig Vargo, Romano Danesi, et al.. (2009). The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Molecular Cancer Therapeutics. 8(9). 2496–2508. 146 indexed citations
18.
Dahut, William L., Charity D. Scripture, Edwin M. Posadas, et al.. (2008). A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer. Clinical Cancer Research. 14(1). 209–214. 142 indexed citations
19.
Bhattacharjee, Kasturi, et al.. (2008). Indirect optic nerve injury in two-wheeler riders in northeast India. Indian Journal of Ophthalmology. 56(6). 475–475. 17 indexed citations
20.
Jain, Lokesh, Erin R. Gardner, Jürgen Venitz, William L. Dahut, & William D. Figg. (2007). Development of a rapid and sensitive LC–MS/MS assay for the determination of sorafenib in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 46(2). 362–367. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gennaro Daniele Breakdown of academic impact, for papers by Pascaline Boudou‐Rouquette Breakdown of academic impact, for papers by Andrew Lake Breakdown of academic impact, for papers by Muhammad Wasif Saif Breakdown of academic impact, for papers by Julie Hambleton Breakdown of academic impact, for papers by Laleh G. Melstrom Breakdown of academic impact, for papers by Ana Ruiz-Garcı́a Breakdown of academic impact, for papers by Michael B. Jameson Breakdown of academic impact, for papers by Gianpiero Fasola
Rankless by CCL
2026